|
|
||||||||
Papers In Press, published online ahead of print September 1, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on August 13, 2002
Medicine, University of Washington, Seattle, WA 98195-6426
Corresponding Author: achait{at}u.washington.edu
Retention of apolipoprotein (apo) B and E-containing lipoproteins by extracellular vascular proteoglycans is a critical step in atherogenesis. In addition, high circulating levels of apo C-III are associated with increased atherosclerosis risk. To test whether apo C-III content of apo B-containing lipoproteins affects their ability to bind to the vascular proteoglycan, biglycan, we evaluated the impact of apo C-III on the interaction of [35S]SO4-biglycan derived from cultured arterial smooth muscle cells with lipoproteins obtained from individuals across a spectrum of lipid concentrations. Using an electrophoretic gel-mobility shift assay, low density lipoproteins (LDL) had the highest affinity for biglycan, followed by intermediate density lipoproteins (IDL) and very low density lipoproteins (VLDL). The extent of biglycan binding correlated positively with the amount of apo C-III within VLDL (r=0.78, p<0.01), IDL (r=0.67, p<0.01) and LDL (r=0.52, p<0.05). Moreover, the biglycan binding of VLDL, IDL, and LDL was reduced after depletion of apo C-III-containing lipoprotein particles in plasma by anti-apo C-III immunoaffinity chromatography. Since apo C-III does not bind biglycan directly, the enhanced biglycan binding may result from a conformational change associated with increased apo C-III content by which apo B and/or E become more accessible to proteoglycans. This may be an intrinsic property of lipoproteins, since exogenous apo C-III enrichment of LDL and VLDL did not increase binding. Apo C-III content may thus be a marker for lipoproteins that are characterized as having an increased ability to bind proteoglycans.
Revised on September 1, 2002
Accepted on August 20, 2002
Apo C-III Content of Apo B-Containing Lipoproteins is Associated with Binding to the Vascular Proteoglycan, Biglycan
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
P. G. Scheffer, T. Teerlink, J. M. Dekker, G. Bos, G. Nijpels, M. Diamant, P. J. Kostense, C. D. A. Stehouwer, and R. J. Heine Increased Plasma Apolipoprotein C-III Concentration Independently Predicts Cardiovascular Mortality: The Hoorn Study Clin. Chem., August 1, 2008; 54(8): 1325 - 1330. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Nakashima, T. N. Wight, and K. Sueishi Early atherosclerosis in humans: role of diffuse intimal thickening and extracellular matrix proteoglycans Cardiovasc Res, July 1, 2008; 79(1): 14 - 23. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Zheng, C. Khoo, K. Ikewaki, and F. M. Sacks Rapid turnover of apolipoprotein C-III-containing triglyceride-rich lipoproteins contributing to the formation of LDL subfractions J. Lipid Res., May 1, 2007; 48(5): 1190 - 1203. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. F Hilpert, S. G West, P. M Kris-Etherton, K. D Hecker, N. M Simpson, and P. Alaupovic Postprandial effect of n-3 polyunsaturated fatty acids on apolipoprotein B-containing lipoproteins and vascular reactivity in type 2 diabetes Am. J. Clinical Nutrition, February 1, 2007; 85(2): 369 - 376. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. A. Ruiz-Narvaez, Y. Yang, Y. Nakanishi, J. Kirchdorfer, and H. Campos APOC3/A5 haplotypes, lipid levels, and risk of myocardial infarction in the Central Valley of Costa Rica J. Lipid Res., December 1, 2005; 46(12): 2605 - 2613. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Davidsson, J. Hulthe, B. Fagerberg, B.-M. Olsson, C. Hallberg, B. Dahllof, and G. Camejo A proteomic study of the apolipoproteins in LDL subclasses in patients with the metabolic syndrome and type 2 diabetes J. Lipid Res., September 1, 2005; 46(9): 1999 - 2006. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. F. Khalil, W. D. Wagner, and I. J. Goldberg Molecular Interactions Leading to Lipoprotein Retention and the Initiation of Atherosclerosis Arterioscler. Thromb. Vasc. Biol., December 1, 2004; 24(12): 2211 - 2218. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. D. Proctor, D. F. Vine, and J. C.L. Mamo Arterial Permeability and Efflux of Apolipoprotein B-Containing Lipoproteins Assessed by In Situ Perfusion and Three-Dimensional Quantitative Confocal Microscopy Arterioscler. Thromb. Vasc. Biol., November 1, 2004; 24(11): 2162 - 2167. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. A. Kaysen and J. P. Eiserich The Role of Oxidative Stress-Altered Lipoprotein Structure and Function and Microinflammation on Cardiovascular Risk in Patients with Minor Renal Dysfunction J. Am. Soc. Nephrol., March 1, 2004; 15(3): 538 - 548. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| All ASBMB Journals | Journal of Biological Chemistry |
| Molecular and Cellular Proteomics | ASBMB Today |